Athersys (NASDAQ:ATHX) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Athersys (NASDAQ:ATHX) in a research report released on Thursday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Athersys Price Performance

Athersys has a one year low of $0.01 and a one year high of $1.99. The stock has a market cap of $833,000.00, a PE ratio of -0.01 and a beta of -0.90.

About Athersys

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.